AzTrials
AzTrials

Feeding BehaviorTIMCNCT03949543

The Timing of Main Meal Consumption Effect on Gut Microbiota and Host

A study testing Large Lunch Intervention and Large Dinner Intervention in people with Feeding Behavior and Gastrointestinal Microbiome, run by University of Glasgow at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The interplay between diet and the gut microbiota has been implicated in the onset of cardiovascular disease. The gut microbiota displays diurnal rhythms, which may be influenced by meal timing. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
What is being tested?
Large Lunch Intervention and Large Dinner Intervention
Could I receive a placebo?
No, everyone receives an active treatment
How many people
17 participants
Where
1 siteUnited Kingdom
Study dates
10 Oct 2017to 28 May 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • 1) Healthy adult people

Who cannot join

  • History of gut surgery
  • Use of antibiotics or steroids the last 3 months
  • Positive or negative energy balance (recent weight gain or loss, ±2 Kg the past month)

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • School of Medicine, University of Glasgow / New Lister Building, Glasgow Royal Infirmary

    Glasgow, G312ER

Other trials in United Kingdom

About this study

Official title: A Randomised Controlled Trial of Meal Timing as an Acute Modifier of the Gut Microbiota and the Cardiometabolic Health of the Host.

The interplay between diet and the gut microbiota has been implicated in the onset of cardiovascular disease. The gut microbiota displays diurnal rhythms, which may be influenced by meal timing. This study aimed to investigate the effect of main meal consumption timing on the microbiota and the cardiometabolic factors of the host using a cross-over RCT in healthy adults

The main outcome measurements will be: a) changes in gut microbiota composition based on 16S rRNA gene amplicon sequencing and shotgun metagenomics, b) changes in bacterial functional capacity) and urinary/faecal metabolomics, c) changes in targeted bacterial metabolites, d)Inflammatory markers

The aim of this study is to explore the effect of the timing of main meal consumption on gut microbiota and immune response in healthy adults.

Read the detailed description

This study will be an open-label, cross-over RCT in healthy adults. Healthy adult (>18 y) participants will be recruited from the community by means of an advertisement leaflet (see associated supporting document-"Advertisement flyer") and word of mouth. The researcher will arrange a meeting with those expressing an interest about the study. The researcher will collect demographic information (e.g. age and gender) and ask the subjects whether they suffer from any acute or chronic illness (defined as illness which requires regular visits to health services) (see associated supporting document-"Health Questionnaire"). If they suffer from a chronic illness they will be excluded. Other exclusion criteria include history of previous of major gut surgery, unstable weight, use of antibiotics or steroids the last 3 months. Participants will be informed about the study at Human Nutrition, New Lister Building, Glasgow Royal Infirmary, or at the University of Glasgow main campus social areas (e.g. Gilchrist). No children will be recruited. Subjects who have expressed an interest about the study but are not suitable to participate will be acknowledged and will receive an explanation as to why they have been excluded.

Following informed written consent, participants will be randomly allocated to intervention groups using the MS Excel "rand()" function. Women will start their intervention on the same phase of their menstrual cycle to avoid the effect of hormonal changes on study outcome.

Dietary interventions: Participants will be asked to undertake two experimental diets. The two dietary interventions are identical with the only difference being the timing of the main meal consumption (dinner and lunch). Participants will follow each diet for a period of one week with a three week washout period between the two interventions. The wash out period aims to drive the gut microbiota characteristics back to baseline levels. The diet will provide the average energy requirements of the participants (Department of Health) and aims to keep participants' weight stable during the study period. All dietary aspects of the study will be designed and supervised by the qualified dietitians/nutritionists, who are members of the research team. Participants will be given a list of meals and snacks to choose from (see associated supporting document-"Food List Preferences"). All meals will be provided to the participants free of charge. Meals will be ordered online by the researchers, using the University of Glasgow Hub, and will be delivered to the participants' residence by the supermarket staff. Weight and height will be measured.

Week 1 Participants will follow a structured diet containing meals of their choice for a week. The participants will select these meals from a list which the researcher will provide to them. The timing of the meal will be specified and the participants will have to complete their meals within 25±5 minutes. The participants will be given written instructions on how to follow the diet (see associated supporting document-"Instruction Sheet" \& "Participant Study Calendar"). Participants will provide all faecal samples produced during days from noon of day 5 to noon of day 8. Fasted blood (6 ml) and urine samples will be collected the day after the end of the Week 1 intervention (i.e. day 8). These will be collected at the Human Nutrition laboratory, at the New Lister Building, Glasgow Royal Infirmary. Weight and height measurements will be repeated.

Week 2, 3 \& 4 During the wash out period, the participants will follow their habitual diet and no research intervention will take place.

Week 5 This will be replication of the dietary intervention and sample collection at Week 1. The only difference is that lunch meal from Week 1 will swap to dinners in Week 5.

Diet compliance: Over the course of the two experimental diets compliance will be monitored by asking participants to complete a "checklist" with their prescribed diet (see associated supporting document-"Compliance Questionnaire"). A gentle reminder call or text will be sent to the participants every 3 days to increase participants' motivation and compliance on the diets.

Sample collection \& analysis: Fresh faecal and urine samples will be collected as described above. The main outcome measurements will be: a) changes in gut microbiota composition based on 16S rRNA gene amplicon sequencing and shotgun metagenomics, b) changes in bacterial functional capacity (whole genome shotgun metagenomics) and urinary/faecal metabolomics, c) changes in targeted bacterial metabolites (short chain fatty acids, sulphide, ammonia, lactate, succinate, ethanol). Blood lipids, appetite hormones, adipokines, and inflammatory markers will be measured using ELISA kits. Stool samples will be collected from participants' homes or delivered to the lab by pre-paid taxi.

Detailed analysis: Genomic DNA will be extracted by the faecal samples using in-house developed assays. The sample will be tested for purity on 1% Agarose gel and the concentration of nucleic acids will be measured with Nanodrop. Amplification of the V4 region of the 16S rRNA gene will be performed in house using PCR and High Fidelity Mastermix and Golay Barcodes. The pooled sample will be sent to the University of Birmingham for 250 bp pair-end sequencing on MiSeq. The data will be analysed by Dr Gerasimidis PDRA in Bioinfomatics. Similarly measurements of SCFA will be performed in acidified ether extracts using Gas Chromatography equipped with an FID detector. Quantification will be performed against authentic standards. Other bacterial metabolites and cardiovascular markers will be assayed with colorometric and enzymatic assays and commercially available ELISA kits as these have been reported previously. https://www.ncbi.nlm.nih.gov/pubmed/28318688 and https://www.ncbi.nlm.nih.gov/pubmed/26119811

Power calculation: An accurate power calculation is impossible to compute due to lack of pilot data. Based on a similar study for a mean difference of 5.4 μmol/g of faecal acetate (SD=5) and 80% power, 20 participants are required. Power calculation will be revised following recruitment and study completion of the first 7 participants.

Being tested
Large Lunch Intervention, Large Dinner Intervention
Medical subject headings
Feeding Behavior

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Large Lunch InterventionOther

    Participants were asked to consume 60% of their daily energy requirements as lunch, between 12:30 and 13:30. Breakfast accounted for 15% of their total daily energy, a morning and evening snack for 5%. 15% was given for light meal either as dinner.

  • Large Dinner InterventionOther

    Participants were asked to consume 60% of their daily energy requirements as dinner, between 19:30 and 20:30, each day during their two dietary interventions. Breakfast accounted for 15% of their total daily energy, a morning and evening snack for 5%. 15% was given for light meal either as lunch.

Study groups in NCT03949543
Study groupRoleWhat they receive
Healthy Adult Participants AExperimentalParticipants who will get two interventional diets, for 7 days each, but allocated to start with large lunch intervention
Receives: Other: Large Lunch Intervention; Other: Large Dinner Intervention
Healthy Adult Participants BExperimentalParticipants who will get two interventional diets, for 7 days each, but allocated to start with large dinner intervention
Receives: Other: Large Lunch Intervention; Other: Large Dinner Intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Gut microbiome alpha diversity

    Shannon diversity index

    Measured: 7 days post-intervention

  2. Faecal short chain fatty acids

    Short chain fatty acids (umol/g)

    Measured: 7 days post-intervention

Secondary outcomes (7)
  1. HDL

    mmol/L

    Measured: 7 days post-intervention

  2. LDL

    mmol/L

    Measured: 7 days post-intervention

  3. Triglycerides

    mmol/L

    Measured: 7 days post-intervention

  4. Glucose

    mmol/L

    Measured: 7 days post-intervention

  5. Insulin

    mU/L

    Measured: 7 days post-intervention

  6. IL-6

    pg/mL

    Measured: 7 days post-intervention

  7. tnf alpha

    pg/mL

    Measured: 7 days post-intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 May 2019
  2. Study start10 Oct 2017
  3. Primary completion28 May 2018
  4. Study completion28 May 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
17 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03949543
Sponsor's protocol ID
200170046
Acronym
TIMC
Status last verified
May 2019
First submitted
9 May 2019
Last updated
15 May 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Large Lunch Intervention and Large Dinner Intervention in people with Feeding Behavior and Gastrointestinal Microbiome, run by University of Glasgow at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 May 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Gut microbiome alpha diversity (time frame: 7 days post-intervention). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in